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acupuncture therapy is the virtual absence of life-threatening 
side effects and complications resulting from its use? How- 
ever, it would be expected that life-threatening cardiovascu- 
lar complications like those in this report (i.e., cardiac 
tamponade) could result from the use of acupuncture nee- 
dles. A previous report 4described a serious complication as 
a consequence of applying needles to the thorax directly, 
which caused cardiac injury and tamponade. Several path- 
ways by which the acupuncture needle could have reached 
the heart can be considered, 2 but we believe that in my 
patient he needle reached the right ventricle via the blood- 
stream from a distant region, eventually penetrating the free 
wall, because of the location of the acupuncture therapy and 
the coexistence of several needles in the pulmonary vascula- 
ture. In patients uch as this, surgical removal of the pins or 
needles in the heart should be attempted because of the high 
mortality rate of needle-related cardiac injury. 2 To facilitate 
successful removal of a needle from the heart, it is necessary 
to define the precise location of the needle before or during 
the operation. Ultrasonography as been reported to be 
useful for the evaluation and management of patients with 
foreign bodies in the heart, 5 although I failed to find the 
cardiac needle before operating using this method. Instead, 
x-ray computed tomography with contrast medium enabled 
me to locate the needle in the heart and greatly facilitated its 
successful removal, although the image was accompanied by 
an object-related artifact. 
In conclusion, physicians involved in acupuncture therapy 
should keep in mind the possible serious cardiac omplica- 
tions reported here. Contrast x-ray computed tomography 
may be useful for imaging the needle in the heart and great 
vessels. 
I thank Drs. Yoshiaki Mori and Tetsuo Hadama of the 
Department of Cardiovascular Surgery at the Oita Medical 
University for their help in treating the patient. 
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LONG-TERM FOLLOW-UP OF APROTININ-SPECIFIC IMMUNOGLOBULIN G ANTIBODIES AFTER 
CARDIAC OPERATIONS 
J. Weipert, MD, a H. Meisner, MD, a M. Jochum, PhD, b and W. Dietrich, MD, c Munich, Germany 
The protease inhibitor aprotinin (Trasylol, Bayer AG, 
Leverknsen, Germany) is used in cardiac operations for 
acquired heart disease to reduce postoperative bleeding 
and allogeneic blood requirement. 1 Aprotinin is a polyba- 
sic polypeptide derived from bovine lung, and antibody 
production in human beings is likely to occur. Recently, 
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deaths resulting from anaphylactic reactions after sys- 
temic aprotinin exposure in cardiac operations have been 
reported. ~However, it is unknown by which pathway these 
reactions are mediated. Because the use of aprotinin at 
initial cardiac operations i widespread, at least in Europe, 
the risk for anaphylactic reactions at aprotinin reexposure 
may be increased. To study parameters to assess patients' 
individual risks for adverse reactions to aprotinin, we 
followed the course of aprotinin-specific antibodies of the 
immunoglobulin (IG) G class for 4 years. 
With institutional approval and after informed consent, 
36 consecutive adult patients having cardiac operations 
could be followed up. Only patients with no previous 
exposure to aprotinin were selected for this study. Blood 
specimens were drawn for the first time dttring their 
postoperative hospital stay or on an outpatient basis, but 
within 4 months after the operation. Four years later these 
patients were reinvestigated. Aprotinin was used accord- 
ing to the following protocol: A test dose of 10,000 KIU of 
aprotinin (1 ml) was given 10 minutes before the first 
bolus. Patients received an initial bolus of 2 × 106 KIU of 
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Table I. Semiquantitative assessment of aprotinin-specific IgG antibodies in 36 patients 
A. Overall ELISA test results 
Median (range) time after exposure 7 days (6-122 days) 
Positive for IgG antibodies 17 (47.2%) 
Questionably positive 7 (19.4%) 
Negative 12 (33.4%) 
B. IgG status at each ELISA test fivm immediately to 4years after the operation 
Change (n): To positive To questionable 
From negative 3 3 
From positive 8 6 
From questionable 3 1 
48 mo (44-51 too) 
14 (38.9%) 
10 (27.7%) 
12 (33.4%) 
To negative 
6 
3 
3 
aprotinin with the start of the operation, followed by an 
infusion of 5 × 105 KIU/hr. Additionally, 2 × 106 KIU of 
aprotinin was added to the pump prime. 
By means of a semiquantitative, indirect enzyme-linked 
immunoassay (ELISA) test, the course of aprotinin-spe- 
cific IgG antibodies was studied. In brief, ELISA plates 
were coated with aprotinin and incubated uring 24 hours 
at 4 ° C. The plates were washed thereafter. Test speci- 
mens were serially diluted (1:2 n) and added to the wells. A 
positive sample with a serial dilution of 1:10 to 1:1200 was 
used to establish a semiquantitative standard curve. After 
an incubation time of 2 hours at 37 ° C, the plates were 
washed again to remove unbound material. Then peroxi- 
dase-conjugated goat antihuman IgG antibodies were 
added and incubated for 3 hours at 37 ° C. After additional 
washings, substrate reaction was achieved with 2,2'-azino- 
bis(3-ethylbenzthiazoline-6-sulfonic ac d) (ABTS) at 
37 ° C and the absorbance was measured after 30 minutes 
at 405 nm. The amount of aprotinin antibodies was 
directly proportional to the colored product. Specific IgG 
antibody titers below a sample dilution of 1:20 were 
considered as being negative, between 1:20 to 1:50 as 
being questionable, and above 1:100 as certainly positive. 
Data are presented as mean + standard eviation. 
Twelve women and 24 men (median age 56 years, 
ranging from 33 to 67 years; coronary artery bypass 
grafting and valve operations) were studied. The final 
amount of aprotinin during extracorporeal circulation was 
5.5 -+ 0.79 × 10 6 KIU. The clinical course of all patients 
was uneventful, and patients were not reexposed to apro- 
tinin. After a median time of 7 days (ranging from 6 to 122 
,,lays) after the operation, 17 patients had positive test 
results and 7 patients had questionably positive test results 
for IgG antibodies (Table I, A). At that time 12 patients 
had negative test results for IgG antibodies. After a 
median of 48 months (ranging from 44 to 51 months) after 
aprotinin exposure, 14 patients had positive blood samples 
and 10 patients had questionably positive blood samples 
for IgG antibodies. In 12 patients no IgG antibodies could 
be found. Also, an intraindividual change of the aprotinin- 
specific IgG antibody status from the first to the second 
investigation period could be observed (Table I, B). All 
patients with a change of the aprotinin-specific IgG status 
from negative to positive or questionably positive were 
tested for the first time within 6 to 9 days after aprotinin 
exposure. At both investigation periods, six (16.7%) pa- 
tients had negative test results for aprotinin-specific IgG 
antibodies. 
Comment. Aprotinin, a polybasic polypeptide, is a nat- 
urally occurring inhibitor of proteolytic enzymes and is 
derived from bovine lungs. The blood-saving effect after 
aprotinin application during cardiac operations with ex- 
tracorporal circulation is well established, a As a xenoge- 
neic protein it possesses antigenic properties, and for the 
cardiac surgical field the incidence of reported anaphylac- 
tic reactions at primary aprotinin exposition is between 
0.5% and 1%. 3 Because of the increasing rate of reopera- 
tions in patients having heart surgery, reliable parameters 
for measuring the patient's individual risk for adverse 
reaction to aprotinin reexposure are desirable. Up to now 
it is unclear which parameter or test systems are able to 
predict the risk of allergic aprotinin reaction. To our 
knowledge, the multicenter study by Ruskowski and col- 
leagues 4 involving 289 patients is the largest study so far. 
This study evaluated the immunologic sequel of aprotinin 
exposure up to 6 months after exposure in patients having 
cardiac operations. At that time the subcutaneous Prick 
test for aprotinin was positive in two patients only. The 
authors concluded that preoperative Prick testing at 
planned aprotinin reexposure might not be sensitive 
enough to predict the patient's risk of adverse aprotinin 
reaction. Aprotinin-specific IgG antibodies were found in 
46% of the patients. However, the contribution for apro- 
tinin-specific IgG antibodies to an allergic reaction to 
aprotinin is not yet established. 4 
During the early period after aprotinin exposure, the 
percentage of patients (47%) with aprotinin-specific IgG 
antibodies in our study was nearly identical to the per- 
centage reported by Ruskowski and coworkers. 4 As early 
as 7 days after aprotinin exposure, positive test results 
could be found. Four years after aprotinin exposure, all 
intraindividual shifts of the IgG test results from positive 
to negative and vice versa were found (Table I, B). 
Although we did not reexpose the patients to aprotinin at 
the second evaluation, one might speculate that patients 
with positive IgG status are still at risk for allergic reaction 
to aprotinin reexposure. This theory is supported by our 
clinical data. The overall risk for adverse reaction to 
aprotinin reexposure was 7 of 248 reexposures (2.8%) and 
the risk for adverse reaction was significantly higher within 
4 months after aprotinin exposure as compared with late 
aprotinin reexposure (6.4% vs 1.9%). 3 
Because of the documented blood-saving effect with 
aprotinin application in cardiac operations, reliable test 
systems are becoming an important issue of the compre- 
hensive management ofpatients with reexposure to apro- 
6 7 8 Brief communications 
The Journal of Thoracic and 
Cardiovascular Surgery 
October 1997 
tinin. We found that 47% and 39% of the patients had 
positive test results for aprotinin-specific IgG antibodies 
early and late after exposition. Not much is known about 
the precise immunologic sequel during an adverse reac- 
tion to aprotinin. Determination of aprotinin-specific IgG 
antibodies might be a useful clinical indicator to identify 
individuals at risk for anaphylactic reactions to aprotinin, 
but more precise methods are desirable. 
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PRIMARY TRACHEAL SYNOVIAL CELL SARCOMA: A FIRST CASE REPORT 
Anne T. Sykes, MD, a Chris K. Rokkas, MD, ~ Andre Kajdacsy-Balla, MD, b and George B. Haasler, MD," 
Milwaukee, Wis. 
Synovial cell sarcoma is a rare soft-tissue tumor com- 
prising only 7% of all soft-tissue sarcomas, with fewer than 
10% of those involving the head and neck. It has never 
been described involving the trachea as the primary site. 
We report here a case of primary tracheal synovial cell 
sarcoma nd review the limited data available on diagno- 
sis, prognosis, and treatment of this tumor. 
Clinical summary. A 20-year-old white male college 
student with a 3-year history of exercise-induced asthma 
was being treated with bronchodilators. Progressive dys- 
pnea, stridor, intermittent hemoptysis, and a 15 kg weight 
loss developed over a 3-month period. Coughing episodes 
elicited anterior chest pain radiating to the back. An 
episode of respiratory distress prompted a visit to the 
emergency department. Results of physical examination 
were remarkable for respiratory stridor and wheezing. 
The patient continued to have symptoms despite systemic 
steroid therapy. Bronchoscopy revealed a smooth, pale, 
soft tracheal tumor extending proximally to 3 cm below 
the true vocal cords, occupying most of the tracheal 
lumen. Computed tomography demonstrated a 3 cm 
intratracheal mass extending outside the tracheal wall, 
with its distal extension 5 cm above the carina (Fig. 1). 
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There was neither clinical nor radiographic evidence of 
lymphadenopathy. 
The patient underwent en bloc tumor excision with 
tracheal resection by a neck approach through a low collar 
incision. Intraoperative bronchoscopy revealed a normal 
distal tracheobronchial tree. Five tracheal rings with clear 
surgical margins of at least 1 cm were removed, and 
primary end-to-end anastomosis was performed. Grossly, 
the mass appeared well circumscribed, with transmural 
extension into the paratracheal region but without gross 
invasion into fat. The patient recovered uneventfully and 
was discharged to home on the fourth postoperative day 
without bronchodilators. Results of metastatic workup, 
including computed tomography of the chest, abdomen, 
and pelvis and a bone scan, were negative. He was 
referred to radiation oncology and received a total of 62 
Gy external beam irradiation in 22 fractions of 180 cGy 
and boost therapy in 12 fractions of 180 cGy. He has not 
been treated with adjuvant chemotherapy. The patient 
remains well 8 months after the operation. 
Pathology. Histologically, the tumor showed biphasic 
growth. The pattern was composed mostly of ill-defined 
interweaving fascicles of monomorphic spindle cells but 
also showed numerous clear-cut foci of cuboidal cells 
forming pseudoglandular dusters (Fig. 2, a). This biphasic 
pattern was even more obvious when immunohisto- 
chemical stains were used to show mutually exclusive 
vimentin-positive spindle cells and the epithelial com- 
ponent positive for low-molecular weight cytokeratin 
and carcinoembryonic antigen (Fig. 2, b). Numerous 
scattered mast cells were seen. Both components of the 
tumor stained negative for intracellular mucin (Alcian 
blue at pH 2.5, periodic aeid-Sehiff, and mucicarmine), 
argyrophilic granules (Grimelius stain), and immuno- 
histochemically for chromogranin, S-100, B72.3, 
smooth-muscle actin, and desmin. 
